Azithromycin

Urethritis, Chancroid, Tonsillitis + 34 more
Treatment
32 FDA approvals
20 Active Studies for Azithromycin

What is Azithromycin

AzithromycinThe Generic name of this drug
Treatment SummaryAzithromycin is an antibiotic used to treat a wide range of bacterial infections, including respiratory, enteric, and genitourinary infections. It belongs to the macrolide family and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring. This helps prevent its metabolism and allows it to be used instead of other macrolides in some cases. In March 2020, a study funded by the French government explored the use of a combination of azithromycin and hydroxychloroquine to treat COVID
Zithromaxis the brand name
Azithromycin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Zithromax
Azithromycin
1994
541

Approved as Treatment by the FDA

Azithromycin, otherwise called Zithromax, is approved by the FDA for 32 uses including Sinusitis and Tonsillitis .
Sinusitis
Tonsillitis
Genus Chlamydia
Haemophilus ducreyi infection
unable to prescribe first line therapy for streptococcus pyogenes tonsillitis
Streptococcus pyogenes
Haemophilus Influenzae Infections
Bacterial Sinusitis
Tonsillitis streptococcal
patients appropriate for oral therapy
Tonsillitis bacterial
Acute Otitis Media (AOM)
genital ulcers caused by haemophilus ducreyi infection
Streptococcal Pharyngitis
Moraxella Catarrhalis Infection
Community Acquired Pneumonia (CAP)
Moraxella catarrhalis
ABDIC protocol
Adults
Streptococcus Pneumoniae Infections
Adult Patients
Genital Ulcer Disease (GUD)
Communicable Diseases
Staphylococcus (S.) Aureus Infection
Pneumococcal Infections
Pneumonia, Mycoplasma
Tonsillitis
Pediatric Patients
Otitis
Sore Throat
Streptococcus pyogenes
Streptococcus Agalactiae Infection

Effectiveness

How Azithromycin Affects PatientsMacrolides are a type of medicine used to treat bacterial infections. They work by stopping bacteria from making proteins, which are needed for them to grow and spread. Azithromycin has additional benefits, as it can also help reduce inflammation related to certain respiratory illnesses.
How Azithromycin works in the bodyAzithromycin is an antibiotic that works by stopping bacteria from making proteins. It does this by preventing the assembly of the bacterial ribosome's 50S subunit. This stops the bacteria from replicating, which in turn helps control various bacterial infections. Azithromycin is especially effective because it is able to stay stable in low pH environments and can therefore stay in your body for longer, allowing it to maintain higher concentrations in your tissues than other antibiotics like erythromycin.

When to interrupt dosage

The prescribed amount of Azithromycin is contingent upon the identified issue, for example Streptococcus Agalactiae Infection, Chlamydia trachomatis and Genus Chlamydia. The dosage likewise fluctuates as per the technique of delivery outlined in the table below.
Condition
Dosage
Administration
Urethritis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Conjunctivitis, Bacterial
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Communicable Diseases
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Streptococcus Agalactiae Infection
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Otitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Chancroid
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Tonsillitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Chlamydia trachomatis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Genus Chlamydia
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Genital Ulcer Disease (GUD)
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Haemophilus ducreyi infection
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Streptococcus pyogenes
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Moraxella catarrhalis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Uterine Cervicitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Sinusitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Adult Patients
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Tonsillitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Bacterial conjunctivitis
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Pneumonia, Mycoplasma
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral
Communicable Diseases
, 600.0 mg, 100.0 mg/mL, 500.0 mg, 10.0 mg/mL, 200.0 mg/mL, 500.0 mg/mL, 250.0 mg, 1000.0 mg, 50.0 mg/mL, 2000.0 mg, 1.0 %, 90.0 mg/mL, 120.0 mg/mL, 250.0 mg/mL
, Oral, Tablet, film coated, Tablet, film coated - Oral, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Ophthalmic, Solution / drops, Solution / drops - Ophthalmic, Powder, for suspension - Oral, Powder, for suspension, Tablet, Tablet - Oral, Injection, Injection - Intravenous, Powder, for solution, Powder, for solution - Oral, Powder, for solution - Intravenous, Capsule, Capsule - Oral, Granule, for suspension, extended release, Granule, for suspension, extended release - Oral, Solution, Solution - Ophthalmic, For suspension, For suspension - Oral, Parenteral, Powder, for suspension - Parenteral, Suspension - Oral, Suspension, Tablet, coated, Tablet, coated - Oral

Warnings

Azithromycin Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Azithromycin may interact with Pulse Frequency
Jaundice, Obstructive
Do Not Combine
prior azithromycin use
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Azithromycin may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Azithromycin may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Azithromycin may interact with Pulse Frequency
There are 20 known major drug interactions with Azithromycin.
Common Azithromycin Drug Interactions
Drug Name
Risk Level
Description
Anagrelide
Major
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Anagrelide.
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Asenapine.
Astemizole
Major
The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Astemizole.
Azithromycin Toxicity & Overdose RiskAzithromycin has an oral LD50 (lowest toxic dose) of greater than 2000mk/kg in rats. Possible major side effects include abnormal heart rhythms and hearing loss. There is also a chance of developing resistance to the drug. Liver toxicity has been reported in rare cases, and caution should be taken when giving the drug to those with decreased liver function. Azithromycin has not been studied in pregnant women, but animal studies have not shown harmful effects on the fetus. It is unknown if the drug is passed through breast milk, so caution should be used when giving the drug to nursing mothers. Animal studies have not found

Azithromycin Novel Uses: Which Conditions Have a Clinical Trial Featuring Azithromycin?

At present, 9 active clinical trials are researching the potential of Azithromycin to treat Moraxella Catarrhalis Infection, Staphylococcus (S.) Aureus Infection and Communicable Diseases.
Condition
Clinical Trials
Trial Phases
Sinusitis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Staphylococcus (S.) Aureus Infection
2 Actively Recruiting
Phase 4, Phase 1
Conjunctivitis, Bacterial
0 Actively Recruiting
Streptococcus pyogenes
0 Actively Recruiting
Moraxella catarrhalis
0 Actively Recruiting
Streptococcus Agalactiae Infection
0 Actively Recruiting
Haemophilus Influenzae Infections
0 Actively Recruiting
Uterine Cervicitis
0 Actively Recruiting
Genital Ulcer Disease (GUD)
0 Actively Recruiting
unable to prescribe first line therapy for streptococcus pyogenes tonsillitis
0 Actively Recruiting
Bacterial conjunctivitis
0 Actively Recruiting
Streptococcus pyogenes
0 Actively Recruiting
Diarrhea
0 Actively Recruiting
Tonsillitis
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
Pediatric Patients
0 Actively Recruiting
Adult Patients
0 Actively Recruiting
Chancroid
0 Actively Recruiting

Patient Q&A Section about azithromycin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is azithromycin a strong antibiotic?

"Azithromycin is a popular antibiotic medication that treats a variety of health conditions by stopping the growth of certain types of bacteria. It is easy to use, generally affordable, and highly effective."

Answered by AI

Why azithromycin is given for 3 days?

"It was concluded that a 3-day regiment of azithromycin prescribed as tablets is just as effective as a 10-day regiment of co-amoxiclav in the treatment of acute lower respiratory tract infections."

Answered by AI

What are the side effects of azithromycin?

"If you're feeling nauseous, stick to simple meals and avoid rich or spicy cuisine while taking this medication. If you experience diarrhea, be sure to drink lots of fluids such as water or juice to prevent dehydration. If you vomit, ... If you lose your appetite, ... If you have a headache, ... If you're feeling dizzy or tired, ... If your sense of taste changes, ..."

Answered by AI

What is a azithromycin used for?

"Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs."

Answered by AI

Clinical Trials for Azithromycin

Image of Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University in Toronto, Canada.

White Potatoes for Glycemic Responses

18 - 65
All Sexes
Toronto, Canada
The purpose of this study is to evaluate the interaction between white potato consumption and meal timing on glycemic response, subjective appetite, and energy intake in adults. The investigators hypothesize that white potatoes will modulate glycemic response, enhance satiety, and mitigate subsequent meal consumption and overall food intake when compared with meals containing low glycemic carbohydrates. Furthermore, they anticipate that the timing of white potato consumption will yield differential effects, with breakfast consumption exerting a more pronounced impact on satiety and subsequent food intake reduction compared to dinner consumption.
Recruiting
Has No Placebo
Centre for Urban Innovation (CUI-109), School of Nutrition, Toronto Metropolitan University
Image of Washington University in St. Louis in St Louis, United States.

Adapted HARP for Falls Prevention

45 - 64
All Sexes
St Louis, MO
The Home Hazard Removal Program (HARP) is an effective fall prevention intervention program which targets home hazard identification/removal. In this study the investigators will examine the effectiveness and implementation potential of HARP, adapted for PwD. Investigators will conduct a pilot randomized control trial (RCT) to test the implementation, cost, and preliminary efficacy of an adapted version of HARP for community-dwelling PwD. The single-blinded feasibility RCT will randomize 40 participants to treatment (adapted HARP) and 40 to a waitlist control group. Data on specific types of fall hazards and resulting home modifications as well as falls and fall-related injuries (collected monthly over 12 months) and fear of falling (collected at baseline and 12 months) will inform the preliminary efficacy of adapted HARP among PwD. To ensure usefulness, relevance, and broad dissemination of findings, the investigators will adopt a "designing for implementation and dissemination" approach. The RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework will guide intervention adaptation, trial design, and future implementation. The Practical Robust Implementation and Sustainability Model (PRISM) guides study development by identifying multi-level contextual factors hypothesized to affect the RE-AIM outcomes.
Recruiting
Has No Placebo
Washington University in St. LouisSusan L Stark, PhD
Have you considered Azithromycin clinical trials? We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.Go to Trials
Image of USC Voice Center in Arcadia, United States.

Voice Therapy for Age-Related Voice Change

18+
All Sexes
Arcadia, CA
This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors. The two primary hypotheses are: 1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face? 2. Can online therapy be a more accessible way for older adults to get help for their voice problems? Adults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through: * Changes in voice function * Patient reports about their voice * Scientific measurements of voice quality * Patient satisfaction with treatment * Impact on quality of life The results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.
Waitlist Available
Has No Placebo
USC Voice Center (+3 Sites)Aaron Rothbart, PhD
Have you considered Azithromycin clinical trials? We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.Go to Trials
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.
Recruiting
Has No Placebo
Loma Linda University Medical Center Troesh Medical CampusElizabeth Johnston Taylor, PhD, FAAN
Have you considered Azithromycin clinical trials? We made a collection of clinical trials featuring Azithromycin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security